Leptin signaling antagonists also appear to improve outcomes in cardiovascular disease: leptin induces thrombotic events in a mouse model of pulmonary embolism, but event frequency is reduced–and overall survival improved–by treatment with a leptin-neutralizing antibody (150). Here, LEP is linked to cardiovascular disorder.